Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Please provide your email address to receive an email when new articles are posted on . Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates ...

MONDAY, Dec. 15, 2025 (HealthDay News) — Doing nothing at all to manage a common fetal heart defect might improve the ...

An estimated 40 percent of this group will die before the age of 2. However, little is known about what causes the development of BPD-PH. “Current screening methods are limited in their ability to ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

For extremely preterm infants with protocol-defined patent ductus arteriosus (PDA), the incidence of death or ...

Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

Abbott has secured the US Food and Drug Administration (FDA) and CE Mark approvals for its Amplatzer Piccolo delivery system, ...

Objective: To provide commentary and reviews and brief discussions in controversial or innovative recent advances in neonatal pharmacotherapy. To discuss cutting edge drug delivery systems that may ...